Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2007-02-01

AUTHORS

Richard S. Finn, Judy Dering, Charles Ginther, Cindy A. Wilson, Padraic Glaspy, Nishan Tchekmedyian, Dennis J. Slamon

ABSTRACT

Dasatinib is an orally active small molecule kinase inhibitor of both the src and abl proteins. To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer cell lines that have been molecular profiled using Agilent Microarrays. They represent both luminal and basal breast cancer subtypes based on the relative gene expression of cytokeratin (CK) 8/CK18 and CK5/CK17, respectively, and those that have undergone an epithelial-to-mesenchymal transition (post-EMT) based on their expression of vimentin and the loss of CKs. When treated with 1 μM dasatinib in vitro 8 of them were highly sensitive (>60% growth inhibition), 10 of them were moderately sensitive (40–59% growth inhibition), and 21 were resistant to dasatinib. A highly significant relationship between breast cancer subtype and sensitivity to dasatinib was observed (χ2 = 9.66 and P = 0.008). Specifically, basal-type and post-EMT breast cancer cell lines were most sensitive to growth inhibition by dasatinib. In an attempt to identify potential predictive markers of dasatinib response other than breast cancer subtype we analyzed the baseline gene expression profiles for differentially expressed genes. We identified a set of three biologically relevant genes whose elevated expression is associated with dasatinib inhibition including moesin, caveolin-1, and yes-associated protein-1 with a sensitivity and specificity of 88 and 86%, respectively. Importantly, these data provide scientific rationale for the clinical development of dasatinib in the treatment of women with “triple-negative” breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab). More... »

PAGES

319-326

Journal

TITLE

Breast Cancer Research and Treatment

ISSUE

3

VOLUME

105

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-006-9463-x

DOI

http://dx.doi.org/10.1007/s10549-006-9463-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041402709

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17268817


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dasatinib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Profiling", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Expression Regulation, Neoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Keratins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proto-Oncogene Proteins c-abl", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrimidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sensitivity and Specificity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vimentin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "src-Family Kinases", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Finn", 
        "givenName": "Richard S.", 
        "id": "sg:person.01000523143.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000523143.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dering", 
        "givenName": "Judy", 
        "id": "sg:person.01235757167.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235757167.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ginther", 
        "givenName": "Charles", 
        "id": "sg:person.01046636343.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046636343.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilson", 
        "givenName": "Cindy A.", 
        "id": "sg:person.01123702211.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123702211.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Glaspy", 
        "givenName": "Padraic", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tchekmedyian", 
        "givenName": "Nishan", 
        "id": "sg:person.01001452602.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001452602.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Slamon", 
        "givenName": "Dennis J.", 
        "id": "sg:person.0736251043.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736251043.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/bcr917", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044838995", 
          "https://doi.org/10.1186/bcr917"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6603291", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005853584", 
          "https://doi.org/10.1038/sj.bjc.6603291"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04296", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028145633", 
          "https://doi.org/10.1038/nature04296"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208080", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036797184", 
          "https://doi.org/10.1038/sj.onc.1208080"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-006-9184-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046838668", 
          "https://doi.org/10.1007/s10549-006-9184-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr1155", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014202425", 
          "https://doi.org/10.1186/bcr1155"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1209254", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041700730", 
          "https://doi.org/10.1038/sj.onc.1209254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208079", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039726511", 
          "https://doi.org/10.1038/sj.onc.1208079"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208076", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029991348", 
          "https://doi.org/10.1038/sj.onc.1208076"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1203912", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036305391", 
          "https://doi.org/10.1038/sj.onc.1203912"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/35021093", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033846543", 
          "https://doi.org/10.1038/35021093"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-02-01", 
    "datePublishedReg": "2007-02-01", 
    "description": "Dasatinib is an orally active small molecule kinase inhibitor of both the src and abl proteins. To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer cell lines that have been molecular profiled using Agilent Microarrays. They represent both luminal and basal breast cancer subtypes based on the relative gene expression of cytokeratin (CK) 8/CK18 and CK5/CK17, respectively, and those that have undergone an epithelial-to-mesenchymal transition (post-EMT) based on their expression of vimentin and the loss of CKs. When treated with 1\u00a0\u03bcM dasatinib in vitro 8 of them were highly sensitive (>60% growth inhibition), 10 of them were moderately sensitive (40\u201359% growth inhibition), and 21 were resistant to dasatinib. A highly significant relationship between breast cancer subtype and sensitivity to dasatinib was observed (\u03c72\u00a0=\u00a09.66 and P\u00a0=\u00a00.008). Specifically, basal-type and post-EMT breast cancer cell lines were most sensitive to growth inhibition by dasatinib. In an attempt to identify potential predictive markers of dasatinib response other than breast cancer subtype we analyzed the baseline gene expression profiles for differentially expressed genes. We identified a set of three biologically relevant genes whose elevated expression is associated with dasatinib inhibition including moesin, caveolin-1, and yes-associated protein-1 with a sensitivity and specificity of 88 and 86%, respectively. Importantly, these data provide scientific rationale for the clinical development of dasatinib in the treatment of women with \u201ctriple-negative\u201d breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab).", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10549-006-9463-x", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435472", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "105"
      }
    ], 
    "keywords": [
      "breast cancer subtypes", 
      "breast cancer cell lines", 
      "cancer cell lines", 
      "cancer subtypes", 
      "breast cancer", 
      "basal breast cancer subtype", 
      "cell lines", 
      "human breast cancer cell lines", 
      "potential predictive marker", 
      "active small-molecule inhibitor", 
      "treatment of women", 
      "expression of vimentin", 
      "small molecule kinase inhibitors", 
      "loss of CK", 
      "predictive marker", 
      "baseline gene expression profiles", 
      "effective treatment", 
      "clinical development", 
      "small molecule inhibitors", 
      "dasatinib", 
      "dasatinib response", 
      "mesenchymal transition", 
      "subtypes", 
      "relative gene expression", 
      "kinase inhibitors", 
      "elevated expression", 
      "scientific rationale", 
      "protein 1", 
      "vitro 8", 
      "potential role", 
      "gene expression profiles", 
      "molecule inhibitors", 
      "Agilent microarrays", 
      "cancer", 
      "growth inhibition", 
      "caveolin-1", 
      "ABL protein", 
      "treatment", 
      "expression profiles", 
      "inhibitors", 
      "inhibition", 
      "Abl kinase", 
      "significant relationship", 
      "gene expression", 
      "expression", 
      "CK17", 
      "relevant genes", 
      "CK18", 
      "vimentin", 
      "women", 
      "Src", 
      "markers", 
      "genes", 
      "sensitivity", 
      "microarray", 
      "specificity", 
      "lines", 
      "response", 
      "rationale", 
      "kinase", 
      "CK", 
      "protein", 
      "role", 
      "moesin", 
      "loss", 
      "profile", 
      "data", 
      "development", 
      "relationship", 
      "growth", 
      "attempt", 
      "transition", 
      "set"
    ], 
    "name": "Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/\u201ctriple-negative\u201d breast cancer cell lines growing in vitro", 
    "pagination": "319-326", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041402709"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-006-9463-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17268817"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-006-9463-x", 
      "https://app.dimensions.ai/details/publication/pub.1041402709"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_454.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10549-006-9463-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9463-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9463-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9463-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9463-x'


 

This table displays all metadata directly associated to this object as RDF triples.

285 TRIPLES      21 PREDICATES      125 URIs      106 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-006-9463-x schema:about N0a3f4035e6634e4980c862f1e774fb0a
2 N11460e027f7a40159d4ebd7b384b4ade
3 N1f75bfd6482b4b96aba7850f8b4dc555
4 N3676b2b7fde6468ca614721fe15f8f01
5 N4d2a91d29fc14d10937bac72a8c0b19e
6 N4d8dae32ea564098be395896fcbf72de
7 N4f99dc5165b4416da57660d3983f57ca
8 N6294790634da4711ab3b27e667fd867d
9 N8e34f024c18447dfbfea45359eeeb4e9
10 N8fc418552c2641bb846039e50ff922db
11 N9d4fdaa848604da59077aadf7332d064
12 Nab131573725f49e7b9d4ef5c3be1abbc
13 Nba61ad740dd14b5c98ea5b063455d58b
14 Nc01979e6b87b47febe6d0f871df1068b
15 Nd39683b1bb80480388bb2ebdc5f109fb
16 Nd41092dbb6134a1e9e52f2d05d67da11
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N5332712b91a64a80bdb227eb633af878
20 schema:citation sg:pub.10.1007/s10549-006-9184-1
21 sg:pub.10.1038/35021093
22 sg:pub.10.1038/nature04296
23 sg:pub.10.1038/sj.bjc.6603291
24 sg:pub.10.1038/sj.onc.1203912
25 sg:pub.10.1038/sj.onc.1208076
26 sg:pub.10.1038/sj.onc.1208079
27 sg:pub.10.1038/sj.onc.1208080
28 sg:pub.10.1038/sj.onc.1209254
29 sg:pub.10.1186/bcr1155
30 sg:pub.10.1186/bcr917
31 schema:datePublished 2007-02-01
32 schema:datePublishedReg 2007-02-01
33 schema:description Dasatinib is an orally active small molecule kinase inhibitor of both the src and abl proteins. To evaluate the potential role of dasatinib in breast cancer we used 39 human breast cancer cell lines that have been molecular profiled using Agilent Microarrays. They represent both luminal and basal breast cancer subtypes based on the relative gene expression of cytokeratin (CK) 8/CK18 and CK5/CK17, respectively, and those that have undergone an epithelial-to-mesenchymal transition (post-EMT) based on their expression of vimentin and the loss of CKs. When treated with 1 μM dasatinib in vitro 8 of them were highly sensitive (>60% growth inhibition), 10 of them were moderately sensitive (40–59% growth inhibition), and 21 were resistant to dasatinib. A highly significant relationship between breast cancer subtype and sensitivity to dasatinib was observed (χ2 = 9.66 and P = 0.008). Specifically, basal-type and post-EMT breast cancer cell lines were most sensitive to growth inhibition by dasatinib. In an attempt to identify potential predictive markers of dasatinib response other than breast cancer subtype we analyzed the baseline gene expression profiles for differentially expressed genes. We identified a set of three biologically relevant genes whose elevated expression is associated with dasatinib inhibition including moesin, caveolin-1, and yes-associated protein-1 with a sensitivity and specificity of 88 and 86%, respectively. Importantly, these data provide scientific rationale for the clinical development of dasatinib in the treatment of women with “triple-negative” breast cancer, a subtype that is categorized as being aggressive and lacking effective treatments (i.e. hormonal manipulation or trastuzumab).
34 schema:genre article
35 schema:isAccessibleForFree true
36 schema:isPartOf N7ad4c05d566a41ed895bea015a56d967
37 Ne392668833df4d28b478f99ebf57d8b7
38 sg:journal.1092777
39 schema:keywords ABL protein
40 Abl kinase
41 Agilent microarrays
42 CK
43 CK17
44 CK18
45 Src
46 active small-molecule inhibitor
47 attempt
48 basal breast cancer subtype
49 baseline gene expression profiles
50 breast cancer
51 breast cancer cell lines
52 breast cancer subtypes
53 cancer
54 cancer cell lines
55 cancer subtypes
56 caveolin-1
57 cell lines
58 clinical development
59 dasatinib
60 dasatinib response
61 data
62 development
63 effective treatment
64 elevated expression
65 expression
66 expression of vimentin
67 expression profiles
68 gene expression
69 gene expression profiles
70 genes
71 growth
72 growth inhibition
73 human breast cancer cell lines
74 inhibition
75 inhibitors
76 kinase
77 kinase inhibitors
78 lines
79 loss
80 loss of CK
81 markers
82 mesenchymal transition
83 microarray
84 moesin
85 molecule inhibitors
86 potential predictive marker
87 potential role
88 predictive marker
89 profile
90 protein
91 protein 1
92 rationale
93 relationship
94 relative gene expression
95 relevant genes
96 response
97 role
98 scientific rationale
99 sensitivity
100 set
101 significant relationship
102 small molecule inhibitors
103 small molecule kinase inhibitors
104 specificity
105 subtypes
106 transition
107 treatment
108 treatment of women
109 vimentin
110 vitro 8
111 women
112 schema:name Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro
113 schema:pagination 319-326
114 schema:productId N29f50c45d041454f84dea577d53fcc55
115 N347b77c4767947578f827e1604e2295b
116 N568ae44a67864c358aa519e945d1a4ea
117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041402709
118 https://doi.org/10.1007/s10549-006-9463-x
119 schema:sdDatePublished 2022-09-02T15:52
120 schema:sdLicense https://scigraph.springernature.com/explorer/license/
121 schema:sdPublisher N3ab8120667fe4f8b9d99e8865341a1c2
122 schema:url https://doi.org/10.1007/s10549-006-9463-x
123 sgo:license sg:explorer/license/
124 sgo:sdDataset articles
125 rdf:type schema:ScholarlyArticle
126 N01d1c01fa79f46bfa7800304520a87b9 rdf:first sg:person.01046636343.30
127 rdf:rest Nd9e74c6216fb459ea0439fbbd44b74cd
128 N05c4e076e69e4f0f8b49a83347bf6ee9 rdf:first N47709e0643ba4c3fa9355030bdc5e6ec
129 rdf:rest N823240e46d36462c85b7e60e5a94f4b3
130 N0a3f4035e6634e4980c862f1e774fb0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Breast Neoplasms
132 rdf:type schema:DefinedTerm
133 N11460e027f7a40159d4ebd7b384b4ade schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Thiazoles
135 rdf:type schema:DefinedTerm
136 N1f75bfd6482b4b96aba7850f8b4dc555 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Gene Expression Regulation, Neoplastic
138 rdf:type schema:DefinedTerm
139 N29f50c45d041454f84dea577d53fcc55 schema:name doi
140 schema:value 10.1007/s10549-006-9463-x
141 rdf:type schema:PropertyValue
142 N347b77c4767947578f827e1604e2295b schema:name pubmed_id
143 schema:value 17268817
144 rdf:type schema:PropertyValue
145 N3676b2b7fde6468ca614721fe15f8f01 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Cell Proliferation
147 rdf:type schema:DefinedTerm
148 N3ab8120667fe4f8b9d99e8865341a1c2 schema:name Springer Nature - SN SciGraph project
149 rdf:type schema:Organization
150 N47709e0643ba4c3fa9355030bdc5e6ec schema:affiliation grid-institutes:grid.19006.3e
151 schema:familyName Glaspy
152 schema:givenName Padraic
153 rdf:type schema:Person
154 N48d6508bb2fb4c67b412c50788cb6647 rdf:first sg:person.01235757167.01
155 rdf:rest N01d1c01fa79f46bfa7800304520a87b9
156 N4d2a91d29fc14d10937bac72a8c0b19e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Keratins
158 rdf:type schema:DefinedTerm
159 N4d8dae32ea564098be395896fcbf72de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Proto-Oncogene Proteins c-abl
161 rdf:type schema:DefinedTerm
162 N4f99dc5165b4416da57660d3983f57ca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name src-Family Kinases
164 rdf:type schema:DefinedTerm
165 N5332712b91a64a80bdb227eb633af878 rdf:first sg:person.01000523143.79
166 rdf:rest N48d6508bb2fb4c67b412c50788cb6647
167 N568ae44a67864c358aa519e945d1a4ea schema:name dimensions_id
168 schema:value pub.1041402709
169 rdf:type schema:PropertyValue
170 N6294790634da4711ab3b27e667fd867d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Cell Line, Tumor
172 rdf:type schema:DefinedTerm
173 N7ad4c05d566a41ed895bea015a56d967 schema:volumeNumber 105
174 rdf:type schema:PublicationVolume
175 N823240e46d36462c85b7e60e5a94f4b3 rdf:first sg:person.01001452602.00
176 rdf:rest N9f7782d158854a4bba649f8ca27d8282
177 N8e34f024c18447dfbfea45359eeeb4e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Dasatinib
179 rdf:type schema:DefinedTerm
180 N8fc418552c2641bb846039e50ff922db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Vimentin
182 rdf:type schema:DefinedTerm
183 N9d4fdaa848604da59077aadf7332d064 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Humans
185 rdf:type schema:DefinedTerm
186 N9f7782d158854a4bba649f8ca27d8282 rdf:first sg:person.0736251043.00
187 rdf:rest rdf:nil
188 Nab131573725f49e7b9d4ef5c3be1abbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Protein Kinase Inhibitors
190 rdf:type schema:DefinedTerm
191 Nba61ad740dd14b5c98ea5b063455d58b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Sensitivity and Specificity
193 rdf:type schema:DefinedTerm
194 Nc01979e6b87b47febe6d0f871df1068b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Administration, Oral
196 rdf:type schema:DefinedTerm
197 Nd39683b1bb80480388bb2ebdc5f109fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
198 schema:name Pyrimidines
199 rdf:type schema:DefinedTerm
200 Nd41092dbb6134a1e9e52f2d05d67da11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
201 schema:name Gene Expression Profiling
202 rdf:type schema:DefinedTerm
203 Nd9e74c6216fb459ea0439fbbd44b74cd rdf:first sg:person.01123702211.44
204 rdf:rest N05c4e076e69e4f0f8b49a83347bf6ee9
205 Ne392668833df4d28b478f99ebf57d8b7 schema:issueNumber 3
206 rdf:type schema:PublicationIssue
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
211 schema:name Oncology and Carcinogenesis
212 rdf:type schema:DefinedTerm
213 sg:grant.2435472 http://pending.schema.org/fundedItem sg:pub.10.1007/s10549-006-9463-x
214 rdf:type schema:MonetaryGrant
215 sg:journal.1092777 schema:issn 0167-6806
216 1573-7217
217 schema:name Breast Cancer Research and Treatment
218 schema:publisher Springer Nature
219 rdf:type schema:Periodical
220 sg:person.01000523143.79 schema:affiliation grid-institutes:grid.19006.3e
221 schema:familyName Finn
222 schema:givenName Richard S.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000523143.79
224 rdf:type schema:Person
225 sg:person.01001452602.00 schema:affiliation grid-institutes:grid.19006.3e
226 schema:familyName Tchekmedyian
227 schema:givenName Nishan
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001452602.00
229 rdf:type schema:Person
230 sg:person.01046636343.30 schema:affiliation grid-institutes:grid.19006.3e
231 schema:familyName Ginther
232 schema:givenName Charles
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046636343.30
234 rdf:type schema:Person
235 sg:person.01123702211.44 schema:affiliation grid-institutes:grid.19006.3e
236 schema:familyName Wilson
237 schema:givenName Cindy A.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123702211.44
239 rdf:type schema:Person
240 sg:person.01235757167.01 schema:affiliation grid-institutes:grid.19006.3e
241 schema:familyName Dering
242 schema:givenName Judy
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235757167.01
244 rdf:type schema:Person
245 sg:person.0736251043.00 schema:affiliation grid-institutes:grid.19006.3e
246 schema:familyName Slamon
247 schema:givenName Dennis J.
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0736251043.00
249 rdf:type schema:Person
250 sg:pub.10.1007/s10549-006-9184-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046838668
251 https://doi.org/10.1007/s10549-006-9184-1
252 rdf:type schema:CreativeWork
253 sg:pub.10.1038/35021093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033846543
254 https://doi.org/10.1038/35021093
255 rdf:type schema:CreativeWork
256 sg:pub.10.1038/nature04296 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028145633
257 https://doi.org/10.1038/nature04296
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/sj.bjc.6603291 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005853584
260 https://doi.org/10.1038/sj.bjc.6603291
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/sj.onc.1203912 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036305391
263 https://doi.org/10.1038/sj.onc.1203912
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/sj.onc.1208076 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029991348
266 https://doi.org/10.1038/sj.onc.1208076
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/sj.onc.1208079 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039726511
269 https://doi.org/10.1038/sj.onc.1208079
270 rdf:type schema:CreativeWork
271 sg:pub.10.1038/sj.onc.1208080 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036797184
272 https://doi.org/10.1038/sj.onc.1208080
273 rdf:type schema:CreativeWork
274 sg:pub.10.1038/sj.onc.1209254 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041700730
275 https://doi.org/10.1038/sj.onc.1209254
276 rdf:type schema:CreativeWork
277 sg:pub.10.1186/bcr1155 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014202425
278 https://doi.org/10.1186/bcr1155
279 rdf:type schema:CreativeWork
280 sg:pub.10.1186/bcr917 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044838995
281 https://doi.org/10.1186/bcr917
282 rdf:type schema:CreativeWork
283 grid-institutes:grid.19006.3e schema:alternateName Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA
284 schema:name Department of Medicine Division of Hematology, Oncology Geffen School of Medicine at UCLA, 10833 Le Conte Ave, 11-934 Factor Bldg, 90095, Los Angeles, CA, USA
285 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...